According to recent findings from the study by Lede BZ et al., parathyroid hormone therapy (PTH) is emerging as an effective treatment for bone loss. Moreover, PTH, when given intermittently, has a substantial anabolic effect on bones.
According to a systematic review by Nam JL et al., which is recently published in Annals of Rheumatic Diseases, disease-modifying anti-rheumatic drugs (DMARDs) are found to be an effective approach in the management of rheumatoid arthritis.
Psoriatic arthritis (PsA) is an autoimmune and chronic inflammatory condition, affecting mostly patients with psoriasis. It results in a broad clinical spectrum, and variable course causes joint pain, stiffness, and swelling. It can affect musculoskeletal structures as well as skin, nails, eyes, and gut. Management of PsA was quite insufficient until some years ago. From last few decades, its management had remarkably changed and improved. It’s all because of earlier diagnosis, progress in pharmacological therapies, and a wider application of a multidisciplinary approach.
A recent study published in Arthritis Care & Research in 2017, has revealed that a typical clinical examination measures and knee pain patterns may indicate underlying patellofemoral (PF) pathology.
A recent 9-month pilot randomized clinical walking trial by Loew L et al., based on a patient treatment preference promoted long-term adherence to a community-based walking program.
- 1 of 146